GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) shares crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $21.23 and traded as low as $20.07. GENMAB A/S/S shares last traded at $20.21, with a volume of 1,813,091 shares.
GENMAB A/S/S Stock Performance
The stock’s 50 day moving average is $21.21 and its two-hundred day moving average is $22.46.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Read More
- Five stocks we like better than GENMAB A/S/S
- Canadian Penny Stocks: Can They Make You Rich?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- The 3 Best Retail Stocks to Shop for in August
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
